Vimarsana
Biggest News Aggregation in the World

Nasdaq Elev News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Elev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Elev Today - Breaking & Trending Today

Short Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Drops By 10.8% - Vimarsana News

Short Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Drops By 10.8%

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 593,500 shares, a decrease of 10.8% from the November 15th total of 665,100 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average trading volume […]

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Down 10.8% in November - Vimarsana News

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Down 10.8% in November

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 593,500 shares, a decline of 10.8% from the November 15th total of 665,100 shares. Based on an average daily trading volume, of 218,500 […]

Caxton Corp Sells 46,599 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Vimarsana News

Caxton Corp Sells 46,599 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV)

Caxton Corp decreased its holdings in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) by 68.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,725 shares of the company’s stock after selling 46,599 shares during the period. Elevation Oncology makes up approximately 0.1% of […]

Elevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by Wedbush - Vimarsana News

Elevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by Wedbush

Wedbush reiterated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. Wedbush also issued estimates for Elevation Oncology’s Q4 2023 earnings at ($0.26) EPS, FY2023 earnings at ($1.21) EPS, Q1 2024 […]

Elevation Oncology (NASDAQ:ELEV) Receives New Coverage from Analysts at HC Wainwright - Vimarsana News

Elevation Oncology (NASDAQ:ELEV) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $1.50 target price on the stock. Elevation Oncology Stock Up 1.9 % ELEV opened at $0.68 on Friday. The firm has […]

Source: wkrb13.com